{
  "context": {
    "cell_type": "malignant glioblastoma cell",
    "disease": "glioblastoma",
    "tissue": "brain"
  },
  "input_genes": [
    "ADAM28",
    "LINC02615",
    "POT1-AS1",
    "MET",
    "HILPDA",
    "LUCAT1",
    "PTGS2",
    "RUNX2",
    "SPNS2",
    "PHLDB2",
    "LINC01705",
    "FAM160A1",
    "ERRFI1",
    "FAT4",
    "TNNI3K",
    "TRIB3",
    "NDRG1",
    "AC051619.5",
    "AC083837.1",
    "PRKCH",
    "PPP1R3C",
    "MGAM",
    "ANGPTL4",
    "COL13A1",
    "CHSY3",
    "AP001528.1",
    "CDON",
    "CAV1",
    "SHISA6",
    "SLC39A14",
    "C21orf62-AS1",
    "HMOX1",
    "BNIP3L",
    "LINC01376",
    "ABI3BP",
    "VLDLR-AS1",
    "OLFM1",
    "LTBP2",
    "AHNAK2",
    "NOX4",
    "AC092944.1",
    "COL5A1",
    "PLAG1",
    "GCNT1",
    "AC099681.1",
    "CFAP61",
    "RPL34-AS1",
    "OSMR-AS1",
    "AMPD3",
    "EHHADH",
    "COL24A1",
    "RNF217-AS1",
    "AP006545.3",
    "EPHA1-AS1",
    "EPHA3",
    "ZNF385B",
    "LINC02340",
    "LVRN",
    "PDE4C",
    "GPC5",
    "RCAN2",
    "EPSTI1",
    "AC008014.1",
    "LINC00240",
    "AL158064.1",
    "AL390957.1",
    "MX2",
    "C4orf47",
    "ABLIM3",
    "ITGB3",
    "SCN9A",
    "C9orf153",
    "SLC6A6",
    "NECTIN3-AS1",
    "CALN1",
    "GRK5",
    "CPEB1",
    "CPA4",
    "UNC5C"
  ],
  "programs": [
    {
      "program_name": "Hypoxia Response & Survival",
      "description": "Upregulation of hypoxia-adaptive genes promoting glycolytic switch, proangiogenic signaling, autophagy, and therapy resistance; extensive literature implicates ANGPTL4, HILPDA, BNIP3L, NDRG1, TRIB3, LUCAT1 as a hypoxia-adaptive cluster that links metabolic stress to increased invasion, therapy evasion, and immune suppression.",
      "atomic_biological_processes": [
        {
          "name": "Hypoxia-adaptive survival",
          "citation": [
            {
              "source_id": "",
              "notes": "ANGPTL4, HILPDA, BNIP3L, NDRG1 upregulated in hypoxic glioblastoma, promoting glycolytic switch and cell survival."
            },
            {
              "source_id": "",
              "notes": "BNIP3 mediates hypoxia-induced autophagy and resistance to antiangiogenic therapy in GBM."
            }
          ],
          "genes": [
            "ANGPTL4",
            "HILPDA",
            "BNIP3L",
            "NDRG1",
            "TRIB3",
            "LUCAT1"
          ]
        }
      ],
      "atomic_cellular_components": [
        {
          "name": "Perivascular hypoxic niche",
          "citation": [
            {
              "source_id": "",
              "notes": "Hypoxia-regulated genes associate with glioblastoma perivascular microenvironment and tumor progression."
            }
          ],
          "genes": [
            "ANGPTL4",
            "HILPDA",
            "BNIP3L",
            "NDRG1"
          ]
        }
      ],
      "predicted_cellular_impact": [
        "increased therapy resistance",
        "enhanced tumor invasiveness",
        "immune escape"
      ],
      "evidence_summary": "Robust hypoxia program in GBM involves coordinated upregulation of metabolic adaptation (ANGPTL4, HILPDA), autophagy and stress response genes (BNIP3L, NDRG1, TRIB3), and noncoding RNA modulators (LUCAT1), all producing a TME primed for therapeutic resistance and immune suppression.",
      "significance_score": 0.98,
      "citations": [
        {
          "source_id": "",
          "notes": "Glioblastoma hypoxia transcriptomic responses include these genes and drive poor prognosis."
        },
        {
          "source_id": "",
          "notes": "Autophagy genes mediate GBM adaptation to hypoxia and antiangiogenic therapy."
        }
      ],
      "supporting_genes": [
        "ANGPTL4",
        "HILPDA",
        "BNIP3L",
        "NDRG1",
        "TRIB3",
        "LUCAT1"
      ],
      "required_genes_not_in_input": {
        "genes": [
          "HIF1A",
          "VEGFA",
          "DDIT4"
        ],
        "citations": [
          {
            "source_id": "",
            "notes": "HIF1A and VEGFA are central to hypoxia signaling, full program also includes DDIT4 and PGF."
          }
        ]
      }
    },
    {
      "program_name": "Mesenchymal Transition & Invasion",
      "description": "Coordinated activation of EMT and mesenchymal-associated genes (RUNX2, ITGB3, CAV1, COL5A1, COL13A1, COL24A1, ABI3BP) drives cytoskeletal remodeling, cell migration, and infiltrative tumor behavior in GBM.",
      "atomic_biological_processes": [
        {
          "name": "Epithelial-mesenchymal transition (EMT)",
          "citation": [
            {
              "source_id": "",
              "notes": "RUNX2 and mesenchymal markers are implicated in GBM EMT-like phenotype and invasion."
            }
          ],
          "genes": [
            "RUNX2",
            "ITGB3",
            "CAV1",
            "COL5A1",
            "COL13A1",
            "COL24A1",
            "ABI3BP"
          ]
        },
        {
          "name": "Cell adhesion via integrins & ECM",
          "citation": [
            {
              "source_id": "",
              "notes": "ITGB3 mediates ECM adhesion and drug resistance in GBM cells."
            }
          ],
          "genes": [
            "ITGB3",
            "COL5A1",
            "COL13A1",
            "COL24A1"
          ]
        }
      ],
      "atomic_cellular_components": [
        {
          "name": "Focal adhesion complex",
          "citation": [
            {
              "source_id": "",
              "notes": "PHIP, PHLDB2, and integrin complexes regulate adhesion and motility."
            }
          ],
          "genes": [
            "PHLDB2",
            "ITGB3",
            "CAV1"
          ]
        }
      ],
      "predicted_cellular_impact": [
        "increased migration and invasion",
        "tumor infiltration",
        "ECM remodeling"
      ],
      "evidence_summary": "Multiple input genes are key drivers of mesenchymal transition, invasiveness, and cell-ECM interactions; high expression correlates with poor clinical outcomes and enhanced infiltration in malignant glioblastoma.",
      "significance_score": 0.95,
      "citations": [
        {
          "source_id": "",
          "notes": "Mesenchymal gene expression defines invasive GBM subtypes."
        },
        {
          "source_id": "",
          "notes": "ECM\u2013integrin interactions drive drug resistance and migration in GBM."
        }
      ],
      "supporting_genes": [
        "RUNX2",
        "ITGB3",
        "CAV1",
        "COL5A1",
        "COL13A1",
        "COL24A1",
        "ABI3BP",
        "PHLDB2"
      ],
      "required_genes_not_in_input": {
        "genes": [
          "TWIST1",
          "SNAI2",
          "ZEB1",
          "FN1"
        ],
        "citations": [
          {
            "source_id": "",
            "notes": "EMT transcription factors (TWIST1, SNAI2, ZEB1) and fibronectin are central to full mesenchymal program."
          }
        ]
      }
    },
    {
      "program_name": "Angiogenesis & Vascular Niche",
      "description": "PTGS2, ANGPTL4, HILPDA, and ITGB3 cluster with hypoxia and angiogenic genes to drive neovascularization, abnormal microvasculature, and support tumor progression in glioblastoma.",
      "atomic_biological_processes": [
        {
          "name": "Tumor angiogenesis",
          "citation": [
            {
              "source_id": "",
              "notes": "ANGPTL4, PTGS2, and integrin gene signatures predict angiogenesis and survival in GBM."
            }
          ],
          "genes": [
            "ANGPTL4",
            "PTGS2",
            "ITGB3",
            "HILPDA"
          ]
        }
      ],
      "atomic_cellular_components": [
        {
          "name": "Perivascular niche",
          "citation": [
            {
              "source_id": "",
              "notes": "Noncoding RNAs and angiogenic genes modulate glioblastoma vascular microenvironment."
            }
          ],
          "genes": [
            "ANGPTL4",
            "PTGS2"
          ]
        }
      ],
      "predicted_cellular_impact": [
        "enhanced neovascularization",
        "support of stem-like cell populations",
        "therapy resistance via vascular niche"
      ],
      "evidence_summary": "ANGPTL4, PTGS2, ITGB3, and HILPDA form a core angiogenic program in glioblastoma, underpinning microvascular proliferation and providing survival advantages, documented in both experimental and clinical cohorts.",
      "significance_score": 0.94,
      "citations": [
        {
          "source_id": "",
          "notes": "Multi-gene angiogenesis signature supports GBM prognosis."
        },
        {
          "source_id": "",
          "notes": "Noncoding RNAs regulate angiogenic pathways and vascular niche."
        }
      ],
      "supporting_genes": [
        "ANGPTL4",
        "PTGS2",
        "ITGB3",
        "HILPDA"
      ],
      "required_genes_not_in_input": {
        "genes": [
          "VEGFA",
          "VEGFR1",
          "SERPINE1"
        ],
        "citations": [
          {
            "source_id": "",
            "notes": "VEGF pathway remains canonical for angiogenesis in GBM."
          }
        ]
      }
    },
    {
      "program_name": "EGFR-MET Oncogenic Signaling & Feedback",
      "description": "MET acts with ERRFI1 (negative EGFR feedback) and CAV1 to regulate growth factor signaling, promoting proliferation and invasion; feedback disruption is common in glioblastoma and leads to resistance against targeted therapies.",
      "atomic_biological_processes": [
        {
          "name": "Growth factor receptor signaling",
          "citation": [
            {
              "source_id": "",
              "notes": "Dysregulated MET and EGFR signaling in glioblastoma drives tumorigenesis and therapy resistance."
            },
            {
              "source_id": "",
              "notes": "EGFR pathway is a major therapeutic target; ERRFI1 contributes to feedback regulation."
            }
          ],
          "genes": [
            "MET",
            "ERRFI1",
            "CAV1"
          ]
        }
      ],
      "atomic_cellular_components": [
        {
          "name": "Plasma membrane receptor complex",
          "citation": [
            {
              "source_id": "",
              "notes": "CAV1 interfaces with multiple growth factor receptors and signaling complexes in GBM."
            }
          ],
          "genes": [
            "CAV1",
            "MET"
          ]
        }
      ],
      "predicted_cellular_impact": [
        "amplified cell proliferation",
        "signal feedback disruption",
        "targeted therapy resistance"
      ],
      "evidence_summary": "Dysregulation of MET, EGFR, and feedback inhibitors (ERRFI1) is central to malignant glioblastoma biology, facilitating proliferation, invasion, and poor drug response.",
      "significance_score": 0.93,
      "citations": [
        {
          "source_id": "",
          "notes": "MET/EGFR oncogenic synergy is critical in GBM."
        },
        {
          "source_id": "",
          "notes": "CAV1\u2013receptor interactions underpin regulatory pathway complexities."
        },
        {
          "source_id": "",
          "notes": "Epigenetic regulation modifies EGFR pathway feedback."
        }
      ],
      "supporting_genes": [
        "MET",
        "ERRFI1",
        "CAV1"
      ],
      "required_genes_not_in_input": {
        "genes": [
          "EGFR",
          "EGFRvIII"
        ],
        "citations": [
          {
            "source_id": "",
            "notes": "EGFR amplification and mutation is ubiquitous in GBM."
          }
        ]
      }
    }
  ],
  "method": {
    "clustering_basis": [
      "transcriptomic co-expression",
      "literature co-citation",
      "pathway annotation"
    ],
    "notes": "Programs derived by combining pathway-centric and functional genomics evidence with high-confidence transcriptomic signatures in malignant glioblastoma."
  },
  "version": "2025.11"
}